Intellia Therapeutics Inc (NASDAQ:NTLA) major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) traded down $0.59 on Thursday, reaching $17.71. 3,324,600 shares of the company were exchanged, compared to its average volume of 365,310. Intellia Therapeutics Inc has a one year low of $10.83 and a one year high of $33.34.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same quarter last year, the business posted ($0.22) EPS. The firm’s revenue for the quarter was up 49.0% on a year-over-year basis. equities analysts forecast that Intellia Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.
NTLA has been the topic of several research reports. Chardan Capital cut shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a report on Tuesday, August 29th. Barclays initiated coverage on shares of Intellia Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $29.00 price objective on the stock. ValuEngine upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Wedbush restated an “ourperform” rating and set a $25.00 price objective (down from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $30.17.
COPYRIGHT VIOLATION WARNING: “Intellia Therapeutics Inc (NTLA) Major Shareholder Sells $27,870,900.00 in Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/14/intellia-therapeutics-inc-ntla-major-shareholder-sells-27870900-00-in-stock.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.